Clinitech laboratory has disclosed another significant share acquisition by its promoter under SEBI regulations. Jagdish Umakant Nayak, who serves as the company's promoter and Managing Director, purchased 6,000 equity shares through open market transactions on March 12-13, 2026, marking his third consecutive acquisition within a week.

Latest Acquisition Details

The recent share purchase was conducted through open market operations over two days, with 2,400 shares acquired on March 12, 2026, and 3,600 shares on March 13, 2026. The transaction was disclosed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011.

Updated Shareholding Position

The latest acquisition resulted in a significant increase in the promoter's shareholding percentage. Before this transaction, Nayak held 7,05,700 shares representing 30.92% of the total voting capital. Post-acquisition, his holding increased to 7,11,700 shares, representing 31.18% of the company's total voting capital.

Cumulative Recent Acquisitions

Combining all recent transactions, Nayak has acquired a total of 18,000 shares (3,600 + 8,400 + 6,000) over multiple days in March 2026. His overall shareholding has increased from the initial 30.39% to 31.18%, representing a cumulative increase of 0.79%.

Regulatory Compliance

The disclosure was submitted to both Clinitech Laboratory Limited and the Bombay Stock Exchange Limited (BSE), where the company's shares are listed. The company's total equity share capital remained unchanged at 22,82,400 shares following all transactions.

Nayak, who holds the position of Managing Director with DIN 00646672, is based in Navi Mumbai, Maharashtra. These systematic acquisitions represent a continued increase in promoter shareholding through market purchases, further strengthening his stake in the laboratory services company.

Clinitech laboratory Limited has announced the successful incorporation of its new subsidiary, Analog IVD Solutions Private Limited, marking a strategic expansion into medical products trade and manufacturing. The Ministry of Corporate Affairs issued the Certificate of Incorporation on February 17, 2026, following the board meeting decision made on February 06, 2026.

Subsidiary Structure and Shareholding

The newly incorporated subsidiary has been established with a well-defined capital structure designed to support its operational objectives. Analog IVD Solutions Private Limited maintains a controlling interest for the parent company while allowing for potential future partnerships.

Business Operations and Objectives

The subsidiary will operate in the medical and pathological products sector, focusing on both trade and manufacturing activities. This strategic move aligns with Clinitech Laboratory's expansion plans in the healthcare industry. The company's memorandum of association clearly defines its primary business objective as trade and manufacturing of medical/pathological products/goods.

Corporate Compliance and Disclosure

The incorporation follows proper regulatory procedures under SEBI (LODR) Regulations, 2015. Chairman and Managing Director Jagdish Umakant Nayak (DIN: 00646672) signed the disclosure documents, ensuring compliance with Regulation 30 requirements for public dissemination of material information.

Strategic Implications

The establishment of Analog IVD Solutions Private Limited represents Clinitech Laboratory's commitment to expanding its presence in the medical products sector. With 60% ownership, the parent company maintains strategic control while positioning itself for growth in the pathological products market. The subsidiary structure provides operational flexibility and focused business development opportunities in the specialized medical equipment and products segment.